Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients

Dilsa Mizrak Kaya, Xiaochuan Dong, Graciela M. Nogueras-González, Yan Xu, Jeannelyn S. Estrella, Kazuto Harada, Anthony Lopez, Fatemeh G. Amlashi, Wayne L. Hofstetter, Dipen M. Maru, Quynh-Nhu Nguyen, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Jeremy J. Erasmus, Irene Thomas, Jane E. Rogers, Shumei Song, Jaffer A. Ajani
  • Cancer Immunology Immunotherapy, July 2017, Springer Science + Business Media
  • DOI: 10.1007/s12032-017-0994-2

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1007/s12032-017-0994-2

The following have contributed to this page: fatemeh Ghazanfari amlashi

In partnership with: